Related Experiment Video
Updated: Aug 10, 2026
11:17
Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
COMPARATIVE GROWTH OUTCOMES OF LONG-ACTING AND SHORT-ACTING GROWTH HORMONE THERAPY IN PEDIATRIC PATIENTS: A 12-MONTH
Acta Endocrinologica (Bucharest, Romania : 2005)
|August 8, 2026
Summary
Long-acting Jintropin and daily Saizen growth hormone therapies show comparable efficacy in children. Combination therapy offers no added benefit, suggesting simpler regimens are sufficient for pediatric growth disorders.
Area of Science:
- Pediatric Endocrinology
- Pharmacology
- Clinical Research
Background:
- Growth hormone (GH) therapy is crucial for pediatric growth disorders.
- Short-acting (Saizen) and long-acting (Jintropin) GH formulations are available.
- Assessing outcomes of different GH treatment regimens is essential.
Purpose of the Study:
- To compare height, weight, and bone age outcomes in children treated with Jintropin, Saizen, or a combination.
- To evaluate the efficacy and safety of long-acting versus short-acting GH therapy.
- To determine if combination therapy offers superior benefits.
Main Methods:
- Retrospective cohort study of 108 children.
- Comparison of Jintropin (n=31), Saizen (n=50), and Combination Therapy (n=27).
- Analyses used ANCOVA and LMM, with Bonferroni correction for post-hoc tests. Safety assessed by ΔBA/ΔCA ratio.
Main Results:
- Annualized growth velocity (GV) was similar across groups: Jintropin (9.30 cm/yr), Saizen (8.55 cm/yr), and Combination (9.56 cm/yr).
- No significant efficacy differences were found between Jintropin vs. Saizen (p=0.501) or Combination vs. Saizen (p=0.160).
- Skeletal safety was confirmed, with no premature epiphyseal fusion indicated by the ΔBA/ΔCA ratio.
Conclusions:
- Long-acting Jintropin monotherapy is comparable and non-inferior to daily Saizen for growth outcomes.
- Jintropin offers a convenient alternative, reducing injection burden.
- Combination therapy did not show statistically superior benefits, suggesting complex regimens may be unnecessary.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:10Nature and Nurture
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...